Coronavirus Disease 2019 (COVID-19)

Articles

• Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection N Engl J Med 2021; 384:289-291
• SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 N Engl J Med 2021; 384:229-237
• REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 N Engl J Med 2021; 384:238-251
• COVID Antibody Drugs Gaining Ground— But still facing substantial challenges to greater clinical uptake MedPage Today February 12, 2021
• Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics National Academies of Sciences, Engineering, and Medicine. 2021. Rapid Expert Consultation on Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January 29, 2021). Washington, DC: The National Academies Press.
• COVID-19 Monoclonal Antibody Treatments: Recommendations and Promising Practices for Providers Duke Margolis Center for Health policy

Combat COVID (HHS)

• Monoclonal Antibodies for High-Risk COVIS-19 Positive Patients (English) (Spanish)

National Institutes of Health (NIH)

• NIH COVID-19 Treatment Guidelines: What's New in the Guidelines

Presentations

• Project ECHO Website. Resources related to monoclonal antibodies and dialysis.

U.S. Federal Drug Administration (FDA)

• Resumption in Use and Distribution of Bamlanivimab/Etesevimab in Certain States
• Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab.
• Emergency Use Authorization (EUA) of Regen-Covtm (casirivimab with imdevimab).